NIIMBL, established under the University of Delaware by the Department of Commerce, focuses on enabling more efficient and flexible manufacturing capabilities for existing and emerging biopharmaceutical products, and developing a world-leading biopharmaceutical manufacturing workforce and their roadmap for biomanufacturing.
Their roadmap for the manufacturing needs and propose a vision of the future for three key topics areas:
- (1) Vaccines
- (2) Antibody-Drug Conjugates (ADC) and Bi-specific Antibodies
- (3) Gene Therapies
For more information on membership, please visit here
Staying Current with NIMBL:
July 3rd - NIIMBL currently has 54 differing projects with call for proposals open. Find out about three currently highlighted by NIMBL as well as a link to view all of the current project opportunities: